… Treatment with once-daily eslicarbazepine acetate 800 mg and 1200 mg was more effective
… in patients with partial-onset seizures refractory to treatment with 1 to 3 concomitant AEDs. …

… Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as adjunctive
therapy … metabolized to its active metabolite, eslicarbazepine, which acts primarily by …

Eslicarbazepine acetate (ESL) is a novel antiepileptic drug indicated for the treatment of …
clinical trials ESL has proven effective as adjunctive therapy in adult patients with refractory of …

… adjunctive treatment of adults aged ≥18 years with partial-onset seizures [4] and in the EU
as adjunctive therapy … of eslicarbazepine acetate when used as adjunctive therapy in patients …

… of eslicarbazepine acetate (ESL) as adjunctive therapy for … weeks despite treatment with
1–2 antiepileptic drugs (AEDs). … pivotal studies with ESL as adjunctive therapy in adults with …

… of ESL as adjunctive treatment of partial-onset seizures as reported in two prior randomized
placebo-controlled trials.11, 12 Once-daily ESL was effective as adjunctive therapy and was …

… Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment
… eslicarbazepine acetate (ESL) as adjunctive therapy in adults with partial-onset seizures. …

… of eslicarbazepine acetate (ESL) as adjunctive therapy in adults with partial-onset seizures.
… In a Phase II adjunctive therapy study in patients with partial epilepsy, once-daily ESL 800 …

… Eslicarbazepine acetate (ESL), a novel sodium channel blocker, is approved for mono and
adjunctive treatment of partial epileptic seizures with or without secondary generalization. Its …

… The aim of this study was to evaluate the safety, tolerability and efficacy of eslicarbazepine
acetate (ESL) as adjunctive therapy in patients aged ≥ 65 years with focal-onset seizures (…